Defining On-Treatment Remission in Plaque Psoriasis: A Consensus Statement From the National Psoriasis Foundation

By afschroeder • June 19, 2025

Armstrong AW, Gondo GC, Merola JF, Roberts AM, Pérez-Chada LM, Balak DMW, Eakin GS, Read C, Le ST, Gutierrez Y, Bhutani T, Blauvelt A, Duffin KC, Fakharzadeh S, Feldman SR, Gelfand JM, Gladman DD, Glick B, Green LJ, Han G, Hawkes JE, Hwang ST, Johnsen N, Kalb RE, Kircik L, Langley RG, Lebwohl MG, Lewitt GM, Maverakis E, Prussick R, Reddy SM, Rosen CF, Scher JU, Siegel EL, Wallace EB, Weinberg JM, Yamauchi PS, Yosipovitch G, Liao W; Remission Workgroup of the National Psoriasis Foundation. Defining On-Treatment Remission in Plaque Psoriasis: A Consensus Statement From the National Psoriasis Foundation. JAMA Dermatol. 2025 Jun 18. doi: 10.1001/jamadermatol.2025.1625. Epub ahead of print. PMID: 40531503.

Tags: Dermatology, Publications

ADAR1 loss-of-function variants altering RNA editing define a new interferon-dependent psoriasis subtype

Assan F, Tragin M, Marella S, Lipecka J, Roger K, Zarhrate M, Bondet V, Nguyen V, Akroun F, Nitschké P, Guerrera IC, Bole C, Izmiryan[...]

A practical inflammatory blood-cell marker for cardiovascular risk stratification in psoriasis: Development of the Platelet-Leukocyte Adjusted Cardiovascular (PLAC) score

Cortes JA, Aflatooni S, Ure A, Palma G, Johnsen N, Smart K, Nong Y, Armstrong AW. A practical inflammatory blood-cell marker for cardiovascular risk stratification[...]

Durability of Response to Icotrokinra in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 Trials

Stein Gold L, Armstrong AW, Soung J, Vender RB, González Cantero Á, Hoffmann M, Guenthner ST, Hong HC, Murrell DF, Song EJ, Kircik L, Augustin[...]